Here’s Why Genmab A/S (GMAB) Rose in Q3
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Global...
Genmab A/S (GMAB)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Orbis Investment Management William B. Gray | 11,078,006 | $339,762,444 | +40% | 1.46% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,643,139 | $111,735,073 | +6% | 0.07% |
| 3. | Renaissance Technologies Jim Simons | 2,821,543 | $86,536,724 | +2% | 0.11% |
| 4. | Ikarian Capital Neil Shahrestani | 175,000 | $53,021,552 | 5.35% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,432,800 | $43,943,976 | -22% | 0.09% |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,818 | $490,491 | 0% | |
| 2. | 11,870 | $365,596 | 0.07% | |
| 3. | 10,655 | $328,174 | 0.04% | |
| 4. | 4,755 | $146,454 | 0.01% | |
| 5. | 291 | $8,963 | 0% |
News See All
Genmab A/S (NASDAQ:GMAB) Q3 2025 Earnings Call Transcript
Operator: Hello, and welcome to the Genmab First Half 2025 Financial Results Conference Call. As a reminder, this conference call is being recorded.
H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to buy. H.C.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDAQ...
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S
Genmab A/S (NASDAQ:GMAB) is strengthening its position as a global leader in antibody-based therapies with both commercial successes and late-stage clinical progress in 2025.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma
Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in antibody-based therapies for cancer and serious diseases, with notable successes including Darzalex (daratumumab) for multiple myeloma...
Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally
Genmab A/S (NASDAQ:GMAB), based in Copenhagen, is a biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases.